Novartis MS Therapy FTY720 Enters Phase III With Lower, Untested Dose
Following delays due to FDA safety concerns, Novartis is moving forward with Phase III trials of its oral multiple sclerosis therapy FTY720, although one of the two doses being evaluated lacks clinical data to support its efficacy
You may also be interested in...
Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue